demonstrated that upregulation of B7-H1 expression is associated with macrophage in LIHC, and anti-inflammatory therapies targeting on TAM or signaling pathways like NF-kB and STAT3 may downregulate the B7-H1 expression on malignant cells and enhance the efficacy of immunotherapy based on tumor-specific CD8+ T cells [44]. The gene discussed is CD8A; the disease is neoplasm.